As Apple (AAPL) Valuation Declined, Holder Kessler Investment Group Lowered Its Holding by $2.51 Million; Franklin Resources Increases Stake in Enanta Pharmaceuticals (ENTA)

May 22, 2018 - By Matt Maslow

Apple Inc. (NASDAQ:AAPL) Logo

Franklin Resources Inc increased its stake in Enanta Pharmaceuticals Inc (ENTA) by 58.85% based on its latest 2017Q4 regulatory filing with the SEC. Franklin Resources Inc bought 117,700 shares as the company’s stock rose 40.76% while stock markets declined. The institutional investor held 317,700 shares of the health care company at the end of 2017Q4, valued at $18.64 million, up from 200,000 at the end of the previous reported quarter. Franklin Resources Inc who had been investing in Enanta Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.94B market cap company. The stock decreased 2.01% or $2.06 during the last trading session, reaching $100.43. About 139,246 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since May 22, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.




Kessler Investment Group Llc decreased its stake in Apple Inc (AAPL) by 25.7% based on its latest 2017Q4 regulatory filing with the SEC. Kessler Investment Group Llc sold 14,855 shares as the company’s stock declined 3.81% with the market. The institutional investor held 42,946 shares of the computer manufacturing company at the end of 2017Q4, valued at $7.27M, down from 57,801 at the end of the previous reported quarter. Kessler Investment Group Llc who had been investing in Apple Inc for a number of months, seems to be less bullish one the $922.23 billion market cap company. It closed at $187.63 lastly. It is down 19.49% since May 22, 2017 and is uptrending. It has outperformed by 7.94% the S&P500.

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.02, from 1.6 in 2017Q3. It dropped, as 12 investors sold ENTA shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported. Sei Invs Commerce, a Pennsylvania-based fund reported 3 shares. 2 are owned by Envestnet Asset. Alps Advsrs stated it has 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Northern Tru Corp accumulated 0% or 200,357 shares. State Board Of Administration Of Florida Retirement accumulated 16,193 shares. Moreover, Principal Group Inc has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 109,959 shares. Texas Permanent School Fund stated it has 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Tiaa Cref Investment Mgmt Ltd owns 38,241 shares. Gradient Invests Lc has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Goldman Sachs Group Incorporated owns 110,304 shares or 0% of their US portfolio. Vanguard reported 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Lazard Asset Mngmt Lc reported 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). The New York-based State Common Retirement Fund has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). The Massachusetts-based Arrowstreet Capital LP has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). D E Shaw & Communication reported 13,374 shares.

Since March 19, 2018, it had 0 insider buys, and 2 sales for $1.14 million activity. Adda Nathalie had sold 4,225 shares worth $361,560 on Monday, April 16.

Franklin Resources Inc, which manages about $208.39 billion US Long portfolio, decreased its stake in Macrogenics Inc (NASDAQ:MGNX) by 22,400 shares to 479,500 shares, valued at $9.11 million in 2017Q4, according to the filing. It also reduced its holding in Xilinx Inc (NASDAQ:XLNX) by 363,264 shares in the quarter, leaving it with 1.32 million shares, and cut its stake in Fortive Corp.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Fool.com which released: “This Small Biotech Is Building on a Surprising Success” on April 24, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” published on May 09, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss” on May 03, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2018 Results – Earnings Call Transcript” published on May 09, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.

Among 6 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Enanta Pharmaceuticals Inc had 24 analyst reports since August 7, 2015 according to SRatingsIntel. JP Morgan downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, February 8 to “Neutral” rating. RBC Capital Markets maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Wednesday, April 4 with “Hold” rating. The firm has “Sector Perform” rating given on Tuesday, January 2 by RBC Capital Markets. The firm has “Hold” rating given on Thursday, February 8 by Robert W. Baird. The rating was downgraded by Barclays Capital on Friday, October 23 to “Underweight”. The firm has “Hold” rating given on Thursday, February 8 by J.P. Morgan. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Mkt Outperform” rating by JMP Securities on Friday, October 23. The rating was maintained by RBC Capital Markets on Friday, October 20 with “Buy”. The firm has “Buy” rating by TheStreet given on Saturday, August 8. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Market Outperform” rating by JMP Securities on Tuesday, July 11.

Kessler Investment Group Llc, which manages about $101.98 million and $79.73M US Long portfolio, upped its stake in Comcast Corp New (NASDAQ:CMCSA) by 43,236 shares to 43,586 shares, valued at $1.75M in 2017Q4, according to the filing.

Investors sentiment increased to 0.73 in Q4 2017. Its up 0.03, from 0.7 in 2017Q3. It increased, as 50 investors sold AAPL shares while 1023 reduced holdings. 151 funds opened positions while 637 raised stakes. 2.98 billion shares or 0.18% more from 2.97 billion shares in 2017Q3 were reported. Colrain Cap Limited Liability Co has invested 5.37% in Apple Inc. (NASDAQ:AAPL). Cadinha Co Ltd Co, a Hawaii-based fund reported 41,072 shares. Counsel Llc New York holds 29,106 shares. Alabama-based Associated Banc has invested 3.31% in Apple Inc. (NASDAQ:AAPL). Amg Tru Bank invested 0.11% in Apple Inc. (NASDAQ:AAPL). Patten Grp Inc Inc owns 2.27% invested in Apple Inc. (NASDAQ:AAPL) for 33,878 shares. Baldwin Mngmt Ltd Liability Company has invested 1.4% in Apple Inc. (NASDAQ:AAPL). Private Management Group Incorporated has 0.01% invested in Apple Inc. (NASDAQ:AAPL) for 1,467 shares. Holt Capital Advsr Ltd Liability Com Dba Holt Capital Ltd Partnership holds 31,437 shares or 1.68% of its portfolio. 1,359 were accumulated by Emory University. Fil Limited stated it has 2.71M shares or 1.28% of all its holdings. Grandfield & Dodd Lc holds 29,202 shares or 0.53% of its portfolio. Brookstone Cap Mngmt accumulated 17,550 shares or 0.27% of the stock. Asset Mngmt Inc, a Michigan-based fund reported 474,685 shares. Amalgamated Financial Bank has 3.11% invested in Apple Inc. (NASDAQ:AAPL) for 679,471 shares.

Analysts await Apple Inc. (NASDAQ:AAPL) to report earnings on August, 7. They expect $2.19 EPS, up 31.14% or $0.52 from last year’s $1.67 per share. AAPL’s profit will be $10.76 billion for 21.42 P/E if the $2.19 EPS becomes a reality. After $2.73 actual EPS reported by Apple Inc. for the previous quarter, Wall Street now forecasts -19.78% negative EPS growth.

Since December 7, 2017, it had 0 insider buys, and 8 sales for $42.88 million activity. SCHILLER PHILIP W had sold 69,491 shares worth $11.56M on Tuesday, April 3. 39,122 Apple Inc. (NASDAQ:AAPL) shares with value of $6.83 million were sold by Maestri Luca. WILLIAMS JEFFREY E also sold $2.90 million worth of Apple Inc. (NASDAQ:AAPL) shares. Riccio Daniel J. sold 15,641 shares worth $2.73M. LEVINSON ARTHUR D sold $6.51M worth of stock.

Apple Inc. (NASDAQ:AAPL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts